In 2023, UBC was selected to lead Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH), one of five national research hubs established with federal funding through the integrated Canada Biomedical Research Fund and Biosciences Research Infrastructure Fund competition.
More than 50 organizations representing the private, public, not-for-profit and academic sectors have come together to form CIEBH, creating a rich environment that will bolster biomedical innovation in Canada.
CIEBH’s vision is to make Canada a global epicentre for developing next-generation immune-based therapeutics that can be rapidly produced domestically, using the latest innovations in biomanufacturing.
Together, CIEBH partners aim to establish a seamless drug development pipeline that will enable Canada to respond to future pandemics and other health challenges in fewer than 100 days.